| 摘要 |
<p>The present invention relates to the use of mimotopes in the treatment of diseases associated with beta-amyloid formation and/or aggregation (beta-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to Abeta1-40/42, AbetapE3-40/42, Abeta3-40/42 and Abeta11-40/42.</p> |
